Cargando…

Inhibition of EGFR and MEK surmounts entrectinib resistance in a brain metastasis model of NTRK1‐rearranged tumor cells

Tropomyosin receptor kinase (TRK) inhibitors have demonstrated histology‐agnostic efficacy in patients with neurotrophic receptor tyrosine kinase (NTRK) gene fusion. Although responses to TRK inhibitors can be dramatic and durable, duration of response may eventually be limited by acquired resistanc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Suzuki, Chiaki, Nishiyama, Akihiro, Arai, Sachiko, Tange, Shoichiro, Tajima, Atsushi, Tanimoto, Azusa, Fukuda, Koji, Takumi, Yohei, Kotani, Hiroshi, Takeuchi, Shinji, Yanagimura, Naohiro, Ohtsubo, Koushiro, Yamamoto, Norio, Omori, Koichi, Yano, Seiji
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	ORIGINAL ARTICLES
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9277414/ https://www.ncbi.nlm.nih.gov/pubmed/35363931 http://dx.doi.org/10.1111/cas.15354

Ejemplares similares

Reduced doses of dabrafenib and trametinib combination therapy for BRAF V600E-mutant non-small cell lung cancer prevent rhabdomyolysis and maintain tumor shrinkage: a case report
por: Adachi, Yuta, et al.
Publicado: (2020)

Bronchoesophageal fistula formation after three courses of nivolumab for carcinoma of unknown primary with a subgroup of lung squamous cell carcinoma
por: Nishiyama, Akihiro, et al.
Publicado: (2020)

MET kinase inhibitor reverses resistance to entrectinib induced by hepatocyte growth factor in tumors with NTRK1 or ROS1 rearrangements
por: Takumi, Yohei, et al.
Publicado: (2022)

Mediastinal Malignant Melanoma Markedly Shrinking in Response to Nivolumab
por: Sakaguchi, Hiroyuki, et al.
Publicado: (2021)

Multiple Malignant Lymphomas of the Bile Duct Developing after Spontaneous Regression of an Autoimmune Pancreatitis-like Mass
por: Ohtsubo, Koushiro, et al.
Publicado: (2020)

Case Report: A case of complete response to entrectinib in NTRK fusion gene-positive parotid gland cancer
por: Moriyama, Etsuko, et al.
Publicado: (2023)

Entrectinib: A Review in NTRK+ Solid Tumours and ROS1+ NSCLC
por: Frampton, James E.
Publicado: (2021)

Patient‐derived xenograft models of non‐small cell lung cancer for evaluating targeted drug sensitivity and resistance
por: Kita, Kenji, et al.
Publicado: (2019)

Correction to: Entrectinib: A Review in NTRK+ Solid Tumours and ROS1+ NSCLC
por: Frampton, James E.
Publicado: (2021)

Response to entrectinib in a malignant glioneuronal tumor with ARHGEF2-NTRK fusion
por: Kurozumi, Kazuhiko, et al.
Publicado: (2022)

Pulmonary carcinosarcoma showing an obvious response to pazopanib: a case report
por: Tanimoto, Azusa, et al.
Publicado: (2018)

The experience of successful treatment of ETV6-NTRK3-positive infant glioblastoma with entrectinib
por: Papusha, Ludmila, et al.
Publicado: (2021)

Entrectinib Induces Apoptosis and Inhibits the Epithelial–Mesenchymal Transition in Gastric Cancer with NTRK Overexpression
por: Sohn, Sung-Hwa, et al.
Publicado: (2021)

Larotrectinib and Entrectinib: TRK Inhibitors for the Treatment of Pediatric and Adult Patients With NTRK Gene Fusion
por: Dunn, Danielle B.
Publicado: (2020)

Entrectinib demonstrates prolonged efficacy in an adult case of radiation-refractory NTRK fusion glioblastoma
por: Grogan, Patrick T, et al.
Publicado: (2022)

Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer
por: Farago, Anna F., et al.
Publicado: (2015)

Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors
por: Demetri, George D., et al.
Publicado: (2022)

STAT3 inhibition suppresses adaptive survival of ALK-rearranged lung cancer cells through transcriptional modulation of apoptosis
por: Yanagimura, Naohiro, et al.
Publicado: (2022)

Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer
por: Sartore-Bianchi, Andrea, et al.
Publicado: (2015)

Entrectinib approval by EMA reinforces options for ROS1 and tumour agnostic NTRK targeted cancer therapies
por: Ardini, Elena, et al.
Publicado: (2020)

Correction: Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients with NTRK Fusion–Positive Solid Tumors
por: Demetri, George D., et al.
Publicado: (2022)

Entrectinib use in a platinum-refractory mucinous ovarian cancer harboring a NTRK3 gene fusion
por: Beck, Olivia G., et al.
Publicado: (2023)

Entrectinib: an orally available, selective tyrosine kinase inhibitor for the treatment of NTRK, ROS1, and ALK fusion-positive solid tumors
por: Liu, Dazhi, et al.
Publicado: (2018)

Cerebrospinal Fluid Penetration and Combination Therapy of Entrectinib for Disseminated ROS1/NTRK-Fusion Positive Pediatric High-Grade Glioma
por: Mayr, Lisa, et al.
Publicado: (2020)

Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG)
por: Desai, Ami V, et al.
Publicado: (2022)

Case report: EML4::NTRK3 gene fusion in a patient with metastatic lung adenocarcinoma successfully treated with entrectinib
por: Lazzari, Chiara, et al.
Publicado: (2022)

Entrectinib for NTRK Fusion-Positive Metastatic Melanoma Progressing on Combined PD-1 and CTLA-4 Inhibition: A Case Report
por: Dawood, Shaheenah, et al.
Publicado: (2023)

Pre‐ and post‐treatment blood‐based genomic landscape of patients with ROS1 or NTRK fusion‐positive solid tumours treated with entrectinib
por: Dziadziuszko, Rafal, et al.
Publicado: (2022)

Proposals for Surmounting Sensor Noises
por: Pittella, Andre, et al.
Publicado: (2023)

In vitro and clinical investigations to determine the drug-drug interaction potential of entrectinib, a small molecule inhibitor of neurotrophic tyrosine receptor kinase (NTRK)
por: Meneses-Lorente, Georgina, et al.
Publicado: (2021)

Survival benefit of combinatorial osimertinib rechallenge and entrectinib in an EGFR‐mutant NSCLC patient with acquired LMNA‐NTRK1 fusion following osimertinib resistance
por: Wang, Jiao‐Li, et al.
Publicado: (2022)

What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC)
por: Drilon, A., et al.
Publicado: (2016)

Glycogen synthase kinase‐3 inhibition overcomes epithelial‐mesenchymal transition‐associated resistance to osimertinib in EGFR‐mutant lung cancer
por: Fukuda, Koji, et al.
Publicado: (2020)

Keeping patients with epilepsy safe: a surmountable challenge?
por: Shankar, Rohit, et al.
Publicado: (2015)

Surmounting structural barriers to tackle endemic infectious diseases
por: Calderón, Felix, et al.
Publicado: (2021)

Development of Neuropathic Arthropathy With Entrectinib: Case Report
por: Giustini, Nicholas P., et al.
Publicado: (2022)

Human biomonitoring data interpretation and ethics; obstacles or surmountable challenges?
por: Sepai, Ovnair, et al.
Publicado: (2008)

Baryon decay: flipped SU(5) surmounts another challenge
por: Ellis, Jonathan Richard, et al.
Publicado: (1990)

Surmounting Chemotherapy and Radioresistance in Chondrosarcoma: Molecular Mechanisms and Therapeutic Targets
por: Onishi, Anne C., et al.
Publicado: (2011)

Neurological disorders and therapeutics targeted to surmount the blood–brain barrier
por: Kanwar, Jagat R, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_iifpjj7c6juijbml8rre1pb5hv